INAB 8-K SEC Filing Analysis

Latest settled — T+20d

INAB ▼ -8.23% at T+20d

NEUTRAL call ✗ call lost -8.23% · α vs SPY -8.25% · entry $1.58 → $1.45

Next anchor: T+60d in 7w

Currently $1.43 · -9.49% from $1.58 entry

Entry anchored
May 7, 2026
via day open

T+1d

+2.85%

call +2.85% · α +2.62%

$1.63

settled 5w ago

T+5d

+0.63%

call +0.63% · α -0.83%

$1.59

settled 4w ago

T+20d

-8.23%

call -8.23% · α -8.25%

$1.45

settled 8d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

IN8bio reported Q1 2026 net loss of $5.1M ($0.26 per share), beating the -$0.59 consensus, driven by lower R&D expenses. Cash stood at $21.9M. Shareholders approved the 2026 equity incentive plan, adding 2.92M shares for future grants. The clinical pipeline continues with GBM data and TCE platform milestones expected in 2026.

Actionable Insight

The EPS beat and reduced cash burn are mildly positive, but the dilutive equity plan and pre-revenue status limit upside. Monitor upcoming ASCO data and FDA guidance in 2H26 for pipeline catalysts.

Key Facts

Q1 2026 net loss of $5.1M, improved from $5.6M YoY
EPS of -$0.26 beat consensus of -$0.59 by 56%
Cash $21.9M as of March 31, 2026 (down from $27.1M at Dec 2025)
Shareholders approved 2026 equity plan, adding 2.92M new shares
R&D expenses decreased to $2.6M from $3.0M YoY
Upcoming ASCO presentation on updated GBM overall survival data

Financial Impact

Q1 net loss $5.1M vs $5.6M YoY improvement; EPS -$0.26 versus -$2.16 prior (adjusted for reverse split).

net lossepscash

Risk Factors

Cash burn rate: $5.1M/quarter implies runway of ~1 year at current spend
Dilution from 2.92M new shares under the 2026 equity plan
No approved products or revenue, entirely dependent on pipeline success
Potential capital needs may require further dilutive financing

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-212128
Document: inab-ex99_1.htm	0001193125-26-212128
Document: inab-20260507.htm	0001193125-26-212128
Document: inab-ex10_2.htm	0001193125-26-212128
Document: 0001193125-26-212128-index-headers.html	0001193125-26-212128
Document: 0001193125-26-212128-index.html	0001193125-26-212128
Document: 0001193125-26-212128.txt	0001193125-26-212128
8-K Data (Synthetic)	0001193125-26-212128

7 reports for INAB

T+1T+5T+20T+60

75% Hit rate 3 of 4 directional calls best @ T+5▲ +16.18%Jun 1, 2026

Filters

Reports for INAB — sortable, filterable
	Type				Now
Jun 3, 2026 10d ago	Press Release NEUTRAL ★ 3/10	$1.54 $1.54	· 0.00%	▼ −0.40%	$1.43 (−7.14%)
Jun 1, 2026 12d ago	8-K BEARISH ★ 6/10	$1.73 $1.56	▲ +9.83%	▲ +9.97%	$1.43 (+17.34%)
Jun 1, 2026 12d ago	424B5 BEARISH ★ 6/10	$1.73 $1.56	▲ +9.83%	▲ +9.97%	$1.43 (+17.34%)
May 18, 2026 25d ago	S-3/A BEARISH ★ 7/10	$1.45 $1.57	▼ −8.28%	▼ −7.24%	$1.43 (+1.38%)
May 7, 2026 5w ago	8-K NEUTRAL ★ 3/10	$1.58 $1.63	▲ +2.85%	▲ +2.62%	$1.43 (−9.49%)
Mar 26, 2026 11w ago	DEFA14A NEUTRAL ★ 3/10	$1.41 $1.37	▼ −2.84%	▼ −2.48%	$1.43 (+1.42%)
Mar 12, 2026 13w ago	Press Release BULLISH ★ 8/10	$1.89 $2.06	▲ +8.99%	▲ +7.97%	$1.43 (−24.34%)

US Market Status

Market Closed — Opens Mon (48h 50m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access